Insights into structure-activity relationships from lipophilicity profiles of pyridin-2(1H)-one analogs of the cardiotonic agent milrinone

European Journal of Pharmaceutical Sciences

Volumn 26, Issue 1, 2005, Pages 78-86

  De Candia, Modesto ^a   Fossa, Paola ^b   Cellamare, Saverio ^a   Mosti, Luisa ^b   Carotti, Angelo ^a   Altomare, Cosimo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Lipophilicity; Milrinone analogs; Positive inotropic effects; Tautomerism

Indexed keywords

CARDIOTONIC AGENT; PYRIDINE DERIVATIVE;

ARTICLE; CORRELATION ANALYSIS; ELECTRON TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IONIZATION; LIPOPHILICITY; PH MEASUREMENT; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

1-OCTANOL; CARDIOTONIC AGENTS; CHLOROFORM; HYDROGEN-ION CONCENTRATION; MILRINONE; POTENTIOMETRY; PYRIDONES; SOLUBILITY; SOLVENTS; STRUCTURE-ACTIVITY RELATIONSHIP; WATER;

EID: 23244455344     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2005.05.001     Document Type: Article

References (42)

1. M.H. Abraham, and H.S. Chadra Applications of a solvation equation to drug transport properties V. Pliska B. Testa H. van de Waterbeemd Lipophilicity in Drug Action and Toxicology 1996 VCH Publishers Weinheim 109 139
2. M.H. Abraham, and J. McGowan The use of characteristic volumes to measure cavity terms in reversed phase liquid chromatography J. Chromatogr. 23 1987 243 246
3. A. Albert, and J.N. Phillips Ionization constants of heterocyclic substances. Part ii. Hydroxy-derivatives of nitrogenous six-membered ring-compound J. Chem. Soc. 1956 1294 1304
4. A.A. Alousi, J.M. Canter, M.J. Montenaro, D.J. Fort, and R.A. Ferrari Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals J. Cardiovasc. Pharmacol. 5 1983 792 803
5. C. Altomare, S. Cellamare, A. Carotti, and M. Ferappi Linear solvation energy relationships in reversed-phase liquid chromatography. Examination of Deltabond C8 as stationary phase for measuring lipophilicity parameters Quant. Struct.-Act. Relat. 12 1993 261 268
6. C. Altomare, S. Cellamare, A. Carotti, and M. Ferappi Linear solvation energy relationships in reversed-phase liquid chromatography. Examination of RP-8 stationary phases for measuring lipophilicity parameters Farmaco 49 1994 394 401
7. C. Altomare, S. Cellamare, L. Summo, P. Fossa, L. Mosti, and A. Carotti Ionization behaviour and tautomerism-dependent lipophilicity of pyridine-2(1H)-one cardiotonic agents Bioorg. Med. Chem. 8 2000 909 916
8. A. Avdeef pH-metric log P. Part 1. Difference plots for determining ion-pair octanol-water partition coefficients of multiprotic substances Quant. Struct.-Act. Relat. 11 1992 510 517
9. A. Avdeef pH-metric log P 2. Refinement of partition coefficients and ionisation constants of multiprotic substances J. Pharm. Sci. 82 1993 183 190
10. A. Avdeef Assessment of distribution pH-profiles V. Pliska B. Testa H. van de Waterbeemd Lipophilicity in Drug Action and Toxicology 1996 VCH Publishers Weinheim 109 139
11. A. Avdeef, K.J. Box, J.E.A. Comer, C. Hibbert, and K.Y. Tam pH-metric log P 10: determination of vesicle membrane-water partition coefficients of ionisable drugs Pharm. Res. 15 1998 209 215
12. R.S. Baker, L. Crombie, R.V. Dove, and D.A. Slack Poliketo-enols and chelates. Synthesis of 2-pyrones, 2-pyridones, 2-methoxypyridines, and m-hydroxyanilines by control of the cyclisation of nitrile-substituted glutaconic types J. Chem. Soc. Perk. T1 1979 677 685
13. R. Boggia, M. Forina, P. Fossa, and L. Mosti Hemometric study and validation strategies in the structure-activity relationships of new cardiotonic agents Quant. Struct.-Act. Relat. 16 1997 201 213
14. F. Bondavalli, O. Bruno, E. Lo Presti, G. Menozzi, and L. Mosti An efficient synthesis of functionalized 2-pyridones by direct route or via amide/enolate ammonium salt intermediates Synthesis 7 1999 1169 1174
15. E. Butt, J. Beltman, D.E. Becker, G.S. Jensen, S.D. Rybalkih, B. Jastorff, and J.A. Beavo Characterization of cyclic nucleotide phosphodiesterases with cyclic AMP analogs: topology of the catalytic sites and comparison with other cyclic AMP-binding proteins Mol. Pharmacol. 47 1995 340 347
16. J. Clark, and D.D. Perrin Prediction of the strengths of organic bases Q. Rev. 18 1964 295 320
17. P. Dorigo, R.M. Gaion, P. Belluco, D. Fraccarollo, I. Maragno, G. Bombieri, F. Benetollo, L. Mosti, and F. Orsini A pharmacological, crystallographic, and quantum chemical study of new inotropic agents J. Med. Chem. 36 1993 2475 2784
18. M. Floreani, P. Fossa, S. Gessi, L. Mosti, P.A. Borea, and P. Dorigo New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase Naunyn-Schmiedeberg's Arch. Pharmacol. 367 2003 109 118 (and literature cited therein)
19. P. Fossa, R. Boggia, E. Lo Presti, L. Mosti, P. Dorigo, and M. Floreani Inotropic agents. Synthesis and structure-activity relationships of new milrinone related cAMP PDE III inhibitors Farmaco 52 1997 523 530
20. P. Fossa, R. Boggia, and L. Mosti Toward the identification of the cardiac cGMP inhibited-phosphodiesterase catalytic site J. Comput. Aided Mol. Des. 12 1998 361 372
21. P. Fossa, F. Giordanetto, G. Menozzi, and L. Mosti Structural basis for selective PDE 3 inhibition: a docking study Quant. Struct.-Act. Relat. 21 2002 267 275
22. P. Fossa, G. Menozzi, P. Dorigo, M. Floreani, and L. Mosti Synthesis and pharmacological characterization of functionalized 2-pyridones structurally related to the cardiotonic agent milrinone Bioorg. Med. Chem. 11 2003 4749 4759
23. F. Giordanetto, P. Fossa, G. Menozzi, S. Schenone, F. Bondavalli, A. Ranise, and L. Mosti Exploring the molecular basis of selectivity in A1 adenosine receptors agonists: a case study J. Comput.-Aided Mol. Des. 17 2003 39 51
24. A. Gordon, A.R. Katritzky, and S.K. Roy Tautomeric Pyridines. Part X. Effects of substituents on pyridone-hydroxypyridine equilibria and pyridone basicity J. Chem Soc. B 1968 556 561
25. A.R. Katritzky, J.D. Rowe, and S.K. Roy Potentially tautomeric pyridines. Part ix. The effect of chlorine substituents on pyridine-hydroxypyridine tautomerism J. Chem Soc. B 1967 758 761
26. S.D. Kraemer, J.-C. Gautier, and P. Saudemon Consideration on the potentiometric log P determination Pharm. Res. 15 1998 1310 1313
27. M. Kuzuya, A. Nogughi, S. Kamiya, and T. Okuda Reactions of 1-unsubstituted tautomeric 2-pyridones with benzyne Chem. Pharm. Bull. 36 1985 2313 2322
28. A. Leo The future of log P calculation V. Pliska B. Testa H. van de Waterbeemd Lipophilicity in Drug Action and Toxicology 1996 VCH Weinheim 157 161
29. A. Leo Evaluating hydrogen-bond donor strength J. Pharm. Sci. 89 2000 1567 1578
30. Lo Presti, E., 2000. Ph.D. dissertation Thesis (English title: 2-Pyridone and 2,5-Quinolindione derivatives as cardiotonics agents acting as cyclic nucleotides phosphodiesterase 3 (PDE3) inhibitors or as A1 adenosine receptor antagonists: rational design, synthesis and preliminary biological evaluation).
31. S.F. Mason The tautomerism of N-heteroaromatic hydroxy compounds. I. Infrared spectra J. Chem. Soc. 1957 4874 4880
32. L. Mosti, R. Boggia, and P. Fossa 2-Pyridone derivatives as inotropic agents: synthesis, pharmacology and molecular modeling study Farmaco 52 1997 331 337 (and references cited therein)
33. L. Mosti, G. Menozzi, P. Schenone, P. Dorigo, R.M. Gaion, F. Benetollo, and G. Bombieri Synthesis and cardiotonic activity of esters of 2-substituted 5-cyano-1,6-dihydro-6-oxo-3-pyridinecarboxylic acids. Crystal structure of 2-methyl, 2-tert-butyl and 2-phenyl esters Eur. J. Med. Chem. 24 1989 517 529
34. L. Mosti, G. Menozzi, P. Schenone, P. Dorigo, R.M. Gaion, and P. Belluco Synthesis and cardiotonic activity of 2-substituted 5-cyano-1,6-dihydro-6-oxo-3- pyridinecarboxylic acids and their methyl or ethyl esters Farmaco 47 1992 427 437
35. L. Mosti, P. Schenone, M.M. Mahiques, P. Dorigo, D. Fraccarollo, G. Santostasi, M. D'Amico, M. Falciani, and E. Lampa Synthesis and pharmacological activities of ethyl 5-cyano-1,6-dihydro-6-oxo-2-(2,3,4-pyridyl)-3- pyridinecarboxylates and derivatives Farmaco 49 1994 559 566
36. L. Mosti, P. Schenone, and G. Menozzi Reaction of 2- dimethylaminomethylene-1,3-diones with dinucleophiles. V. Synthesis of 5-acyl-1,2-dihydro-2-oxo-3-pyridinecarbonitriles and 1,2,5,6,7,8-hexahydro-2,5- dioxo-3-quinolinecarboxamides J. Heterocycl. Chem. 22 1985 1503 1509
37. F. Orsini, F. Benetollo, G. Bombieri, and L. Mosti Cardiotonic agents: a crystallographic and quantum-chemical study of ethyl 5-cyano-1,6-dihydro-2- isopropyl-6-oxo-3-pyridinecarboxylate and related compounds Eur. J. Med. Chem. 25 1990 425 429
38. F. Orsini, F. Benetollo, G. Bombieri, and L. Mosti Conformational analysis and inotropic activity of 2-substituted-5-cyano-1,6-dihydro-6-oxo-3- pyridinecarboxylates II Eur. J. Med. Chem. 28 1993 637 641
39. W.P. Purcell, G.E. Bass, and J.M. Clayton Experimental determination of partition coefficients Strategy of Drug Design. A Molecular Guide to Biological Activity, App. I 1973 Wiley New York pp. 126-142
40. a values and the lipophilicity of ampholytes ion pairs B. Testa H. van de Waterbeemd G. Folkers R. Guy Pharmacokinetic Optimization in Drug Research 2001 Wiley-VCH Publishers Weinheim 351 381
41. a determination of water-insoluble compounds. Validation study in methanol/water mixtures Int. J. Pharm. 151 1997 235 248
42. S.G. Williams, and F.E. Norrington Determination of positional weighting factors for the Swain and Lupton substituent constants F and R J. Am. Chem. Soc. 98 1976 508 516